Viatris, amid strategic overhaul, inks deals to divest 3 businesses for $3.37B zbecker Mon, 10/02/2023 – 15:50 More: Viatris, amid strategic overhaul, inks deals to divest 3 businesses for .37B Source: fierce
read moreICER weighs in on Medicare price negotiations with new appraisals of BMS’ Eliquis, J&J’s Xarelto fkansteiner Mon, 10/02/2023 – 14:14 More: ICER weighs in on Medicare price negotiations with new appraisals of BMS' Eliquis, J&J's Xarelto Source: fierce
read moreWith FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam esagonowsky Mon, 10/02/2023 – 13:15 More: With FDA nod for rare disease drug Rivfloza, Novo Nordisk eyes showdown with Alnylam Source: fierce
read moreJohnson & Johnson says it won’t enforce secondary patents on tuberculosis med Sirturo zbecker Mon, 10/02/2023 – 11:06 More: Johnson & Johnson says it won't enforce secondary patents on tuberculosis med Sirturo Source: fierce
read moreThe proposed changes could limit patients’s access to treatments and clinical trials More: NERA Economic Consulting raises concerns over DHSC’s Statutory Scheme Source: News
read moreThe study analysed and compared information from 65,000 MS patients More: Fewer MS patients are prescribed DMTs in UK compared to Europe Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals